OKYO Pharma's Urcosimod Abstract Selected for Presentation at ARVO 2026

OKYO Pharma's abstract on urcosimod's efficacy in treating neuropathic corneal pain has been accepted for presentation at the ARVO 2026 Annual Meeting. The Phase 2a trial showed clinically meaningful pain reduction and quality-of-life improvement in NCP patients. Urcosimod is a non-opioid, preservative-free eye-drop therapy with dual pain-relieving and anti-inflammatory activity. The company plans to initiate a ~150 subject Phase 2b/3 multiple-dose study in the first half of this year.